Muvon Therapeutics announces the appointment of Marcus Droege as Chief Commercial Officer
- Jun 10
- 1 min
MUVON featured by founded.ch
- May 31
- 1 min
MUVON featured by Nature Biotechnology
- Mar 27
- 1 min
A potential gamechanger in stress urinary incontinence (article published in Leading Opintions Gynäkologie und Geburtshilfe)
- Dec 7, 2023
- 1 min
Ladies Drive Interview with Deana Mohr & Jenny Prange on Female Innovator of the Year Award
- Sep 26, 2023
- 2 min
MUVON joins EAU’s Urge to Act campaign during Urology Week
- Sep 22, 2023
- 1 min
Deana Mohr and Jenny Prange win Female Innovator of the Year Award
- Sep 12, 2023
- 1 min
MUVON's CEO & CTO nominated for Female Innovator of the Year Award
- Sep 7, 2023
- 1 min
MUVON enters TOP 100 SWISS STARTUPS list as a top 3 Biotech
- Jun 12, 2023
- 1 min
MUVON Therapeutics AG among the TOP 3 Swiss biotech leaders according to public voting
- Jun 2, 2023
- 1 min
MUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023 with our tissue engineering therapy
- Apr 24, 2023
- 1 min
First in Human trial results published, demonstrating safety and feasibility of MUVON's SUI Therapy
- Feb 6, 2023
- 1 min
MUVON Therapeutics nominated as finalist for 2023 ZKB Pionierpreis
- Dec 22, 2022
- 1 min
The leadership from MUVON Therapeutics AG will be attending JP Morgan Healthcare week in Jan 2023
- Nov 16, 2022
- 3 min
MUVON Therapeutics announces appointments to its Board of Directors and Scientific Advisory Board
- Oct 27, 2022
- 3 min
Muvon Therapeutics Announces First Patient Enrolled in Phase II Clinical Study
- Sep 19, 2022
- 1 min
CEO Deana Mohr honored to present MUVON to Prof. Shinya Yamanaka, godfather of iPSCs
- Sep 8, 2022
- 3 min
Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with SUI
- Jul 19, 2022
- 1 min
Joint statement by the leading patient group WFIPP and MUVON Therapeutics AG